The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: -0.10 (-6.06%)
Spread: 0.10 (6.667%)
Open: 1.65
High: 1.65
Low: 1.55
Prev. Close: 1.65
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Start of Trading on the OTCQB Venture Market

1 Sep 2021 10:00

RNS Number : 3752K
IQ-AI Limited
01 September 2021
 

September 1, 2021

IQ-AI Limited

("IQ-AI" or the "Company")

 

IQ-AI shares to commence trading on the OTCQB Venture Market in the United States

 

IQ-AI Limited (LSE: IQAI) is pleased to announce that the Company's ordinary shares will today begin trading on the OTCQB Venture Market ("OTCQB") in the United States, under the ticker symbol "IQAIF".

 

The Company's objective in listing its shares on the OTCQB is to provide more efficient access to a new and materially larger pool of prospective US investors. The Directors believe that IQ-AI's OTCQB listing will enable the Company to engage with a significant network of US investors, data distributors and media partners, ensuring that US investors have access to the same level of information and disclosure that is available to investors in the United Kingdom.

 

The OTCQB trading facility is provided through OTC Markets Group Inc, located in New York. OTC Markets Group Inc. operates the world's largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Independent studies show that trading on the OTCQB by an international company offers a positive effect on the liquidity of its shares.

 

Trading on the OTCQB market will have no impact on the IQ-AI ordinary shares admitted to listing on the London Stock Exchange's Main Market under the symbol "IQAI", and no new ordinary shares have been admitted as part of the OTCQB listing. The Company will continue to rely on the announcements and disclosures it makes to the London Stock Exchange and has no Sarbanes-Oxley or SEC reporting requirements.

 

IQ-AI CEO, Trevor Brown, commented:

 

"The United States is home to some of the world's most influential medical technology investors. By joining OTCQB, we now have an effective platform from which to reach a significantly larger investor audience and we look forward to providing investors in both the UK and the United States with regular progress updates at this exciting and pivotal time for the Company."

 

Jonathan Dickson, VP of International Corporate Services at OTC Markets, said:

 

"Congratulations to IQ-AI Ltd on joining the OTCQB Venture Market. We are pleased to support innovative and entrepreneurial international companies seeking to strengthen transparency and to provide better access to disclosure and trading for investors in the United States. Cross-trading on OTCQB in the U.S will enable IQ-AI, which is listed on the London Stock Exchange's Main Market, to diversify its investor base and to expand its global engagement even further."

 

The Company would like to thank Nikolaos Galanopoulos of Galanopoulos & Company, the corporate securities law firm that acted as Sponsor for the Company's application to commence cross-trading on the OTCQB.

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

IQ-AI Limited

Trevor Brown/Dr Qu Li/Vinod Kaushal

 

0207 469 0930

 

Peterhouse Capital Limited

Lucy Williams/Heena Karani

 

0207 220 9797

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDZGGLRMMGMZG
Date   Source Headline
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial
2nd Sep 20217:00 amRNSBoard Changes
1st Sep 202110:00 amRNSStart of Trading on the OTCQB Venture Market
27th Aug 20219:57 amRNSHalf Yearly Report
11th Jun 20214:41 pmRNSSecond Price Monitoring Extn
11th Jun 20214:36 pmRNSPrice Monitoring Extension
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:05 amRNSSecond Price Monitoring Extn
11th Jun 202111:00 amRNSPrice Monitoring Extension
11th Jun 20218:00 amRNSIQAI Awarded “Gad-Free” Patent
4th Jun 20217:00 amRNSIB Software Chosen by LA County Hospital
19th May 202112:06 pmRNSResult of AGM
27th Apr 20213:27 pmRNSNotice of AGM
20th Apr 202110:21 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:27 amRNSIQAI commits to Phase 1 study
6th Apr 20217:00 amRNSFive Year NCI Award Grant to IB
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension
5th Feb 20212:05 pmRNSSecond Price Monitoring Extn
5th Feb 20212:01 pmRNSPrice Monitoring Extension
5th Feb 20219:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.